Objective: Endovascular therapy has recently become standard therapy for select patients with acute ischemic stroke. Infarcted brain tissue may undergo hemorrhagic transformation (HT) after endovascular therapy. We investigated the association between HT and occurrence of poststroke seizures in patients treated with endovascular therapy. Methods: Consecutive patients treated with endovascular therapy for acute anterior circulation ischemic stroke were included. HT was assessed with computed tomography/magnetic resonance imaging (CT/MRI) at 24 h after stroke onset.
| INTRODUCTION
The management of acute ischemic stroke is undergoing a paradigm shift. Based on the recent reports of several randomized controlled trials, including one performed at our center, 1 endovascular therapy, alone or in combination with intravenous thrombolysis, has become standard therapy for selected patients. 2 It is well recognized that reperfusion techniques may be associated with hemorrhagic complications. Hemorrhagic transformation (HT) is a natural consequence of cerebral infarction. 3 HT occurs because of the disruption of the blood-brain barrier following hyperperfusion and may result in neurological decline. 3 Although symptomatic HT (also referred to as symptomatic intracerebral hemorrhage [sICH] ) is recognized to negatively impact outcomes, 4 there is evidence to suggest that HT without immediate symptoms may also be clinically relevant in the long-term. 5, 6 Few studies have investigated the outcomes of HT following endovascular therapy. Although endovascular therapy does not seem to increase the risk of symptomatic HT compared to medical management without endovascular therapy, 7 the overall rates of HT (regardless of symptoms)
after endovascular therapy and its clinical implications have not been well studied. Better understanding of the consequences of HT after endovascular therapy is essential for early prognostication and management of long-term complications.
Poststroke seizures are one of the stated major complications of stroke. Overall, 2.3-14% of patients with stroke develop seizures, 8 which are associated with increased mortality and morbidity. 9 Previous studies have reported an association between hemorrhagic lesions after medically managed strokes (strokes treated by noninterventional methods such as intravenous thrombolysis) and seizures. 10, 11 However, the rates and risk factors of seizures after endovascular therapy have yet to be studied. The difference in revascularization technique may result in altered association of hemorrhage and seizures, as there are suggestions that more successful reperfusion strategies may result in greater rates of HT. 12 Furthermore, the pathophysiology of hemorrhage from mechanical reperfusion is different from that of drug-induced thrombolysis due to suggestions of direct damage from catheter manipulation as well as contrast injections potentially causing degradation of the basal lamina. 13 Therefore, the impact of hemorrhage after endovascular therapy on clinical outcomes warrants separate investigation. We report the first study to analyze poststroke seizures in patients treated with modern cerebrovascular stent devices and revascularization techniques, with the specific aim of assessing the association between HT and the development of poststroke seizures in this setting.
| METHODS

| Study design and setting
This was an observational study conducted at the Royal Melbourne Hospital, which provides secondary and tertiary care to individuals 18 years of age and older. The hospital's comprehensive stroke center serves as the state-wide referral center for endovascular therapy, providing neurointervention service 24 h a day in Victoria, where 6 million people reside. All patients undergoing endovascular therapy are prospectively enrolled into a database. Ethical approval of the study was granted by the Melbourne Health Human Research Ethics Committee (project number QA2010089).
| Patients
Consecutive patients from 2008 to 2016 were eligible for inclusion in the analysis. We included patients with acute cerebral infarcts in the anterior circulation territory secondary to large artery occlusion, who underwent endovascular therapy within 6 h of stroke onset, with or without pretreatment with intravenous tissue plasminogen activator (IV-tPA). Patients with hemorrhage identified on acute imaging were not eligible for this treatment pathway and were excluded. Endovascular therapy was predominantly in the form of endovascular clot retrieval (ECR). However, other intraarterial therapies such as intraarterial thrombolysis and percutaneous transluminal angioplasty were included exclusively or in addition to ECR. Patients with posterior circulation infarcts, prior history of seizures, repeated procedures for recurring strokes, without posttreatment reperfusion grade, or for whom the procedure was aborted due to technical reasons were excluded.
| Imaging protocols and evaluation
Patients routinely underwent neuroimaging between 24 and 48 h after endovascular intervention. In general, patients underwent noncontrast computed tomography (NCCT) using a Siemens Somatom multidetector scanner (Siemens, Erlangen, Germany) with 5-mm-thick slices. Depending on clinical indication, a minority of patients underwent diffusion-weighted imaging (DWI) on magnetic resonance imaging (MRI) for the generation of DWI, b = 0, and apparent diffusion coefficient maps. These were acquired with a 1.5-T scanner (Sigma, GE Healthcare, Milwaukee, WI, USA) with 5-mm-thick slices, with repetition time (TR) 6600 msec and echo time (TE) 57 msec. • Significance: HT has the potential to be used as an imaging biomarker for poststroke seizures Three neurointerventionists, blinded to seizure information, determined the presence of HT on the NCCT or MR-DWI scans by consensus. HT was recorded as any amount of blood present in the treated infarcted area, observed in at least 2 adjacent slices. The Hounsfield unit scale was employed to distinguish between angiographic contrast extravasation, hemorrhage, or a mixture of both. In instances where the distinction was not possible, or when further neuroimaging was required on clinical grounds, NCCT or MR-DWI scans that were acquired within 24 h of the initial follow-up scan were assessed instead. The degree of HT was classified into HI (petechial hemorrhage without space-occupying effect) or PH (hemorrhage with mass effect) in accordance with The European Cooperative Acute Stroke Study (ECASS), 14 with further subclassification based on size of the hemorrhage. Symptomatic HT is conventionally defined by many studies as symptomatic neurological deterioration in combination with a large radiological hematoma on ECASS classification. 15 Consequently, this definition excludes certain cases of asymptomatic HT despite being radiologically large. Furthermore, because of the subjective nature of determining neurological symptoms as well as evidence of HT without symptoms as being clinically relevant, 5, 6 we have solely considered radiological criteria without considering the presence of associated symptoms.
| Seizure ascertainment
Previous studies suggest the highest risk of development of poststroke seizures is within the first year. 16 To ensure complete capture of seizure occurrence, we ascertained whether patients had experienced poststroke seizures up to 2 years from stroke onset. Patients and/or their families were contacted over the telephone using a standardized questionnaire modified from our previous studies [17] [18] [19] and a validated screening questionnaire. 20 The questionnaire included details regarding seizure recurrence and the use of antiepileptic drugs (AEDs). Information obtained from the telephone interview was corroborated with clinical records, either from hospital correspondence or from patients' primary care physicians. Events were recorded as seizures if the symptoms included motor or autonomic components, with or without impairment of consciousness, as defined by the International League Against Epilepsy (ILAE). 21 Final determination was made by an epileptologist blinded to the imaging data.
| Statistical analysis
Comparisons between the HT and non-HT groups were made using Fisher's exact test for categorical variables and Wilcoxon Mann-Whitney test for continuous variables. The association between HT and time to first seizure (censored at 2 years) was investigated using 3 | RESULTS
| Patient characteristics
A total of 216 patients met the inclusion criteria. Eleven patients were subsequently excluded: 1 had previous seizures, 3 had repeated procedures for recurring stroke, and 7 had procedures aborted. There were no relevant significant differences in baseline characteristics between those included and excluded. The analysis was performed on the remaining 205 patients (Figure 1 ). A total of 92 patients received IVtPA and 175 received ECR, with 52 patients (25.4%) receiving both IV-tPA and ECR and 40 patients (19.5%) receiving ECR exclusively without other treatment. One hundred two patients received intraarterial therapy, of whom 59 received percutaneous transluminal angioplasty and 52 received intraarterial thrombolysis. Their median age was 69 years (interquartile range [IQR] 57-78) and 57% were male. Median NIHSS grade was 17 (IQR 13-21). The assessment for HT was based on follow-up NCCT in 182 patients (88.7%) and on MR-DWI in 22 patients (10.7%). The acute (preendovascular) NCCT scan was used for analysis in one patient due to the unavailability of the follow-up scan. HT was detected in 56 patients (27.3%). All the HT was infarct related, with 4 patients having additional HT remote to the infarct. Baseline characteristics of patients with and without HT are summarized in Table 1 . The former group had higher rates of cortical involvement and poststroke seizures. Based on ECASS classification of HT, 14 12, 26, 10, and 8 patients were classified as HI1, HI2, PH1, and PH2, respectively (Table 2 ). with HT and 22 without HT). Of the 205 patients, 16 (7.8%) had developed seizures by 2 years from stroke onset. All 16 patients were treated with AEDs after initial seizure onset. Three additional patients without seizures were also commenced on AEDs prophylactically: 2 following decompressive hemicraniectomy and 1 for mood disturbance. In the 16 patients who developed seizures within the follow-up period, median time from stroke to seizure occurrence was 79 days (IQR 3-366). The median time to first seizure was 111 days (IQR 28-369) in the 10 patients with HT and seizures, and 36 days (IQR 1-183) in the 6 patients without HT. Table 2 shows the classification of HT in patients with and without poststroke seizures.
| Poststroke seizures
| Hemorrhagic transformation and seizure development
Ten of 56 patients (17.9%) with HT developed poststroke seizures compared with 6 of 149 patients (4.0%) without HT. Three patients in the HT group had seizures before death. The Kaplan-Meier analysis is shown in Figure 2 . Upon univariate analysis, HT was associated with a higher rate of development of poststroke seizures (hazard ratio [HR] 5.52, 95% CI 2.00-15.22; P = .001). On multivariable analysis (Table 3) , HT remained significantly associated with a higher rate of development of poststroke seizures (HR 4.85, 95% CI 1.60-14.76; P = .005). At the prevalence level of HT being 7.8%, HT had a high negative predictive value on seizure development of 96.0% (95% CI 91.4-98.5%), with a positive predictive value of 17.9% (95% CI 8.9-30.4%) on seizure development.
| DISCUSSION
This study investigated the development of poststroke seizures in patients with acute ischemic stroke treated with endovascular therapy. Our study is timely given the increasing adoption of endovascular therapy in acute stroke management. We found that HT was statistically associated with an increased rate of seizure development within the 2-year period. This is consistent with previous studies [24] [25] [26] that included populations of ischemic stroke patients who were treated with medical therapy alone.
Findings from our study suggest that seizure risk associated with HT after endovascular therapy may be comparable to that reported in patients without endovascular therapy. If this observation is confirmed in larger studies, this may imply that the presence of stents after endovascular therapy, the possibility of endothelial damage as a result of catheter devices in cerebral vessels, 27 or any other specific insults of endovascular therapy compared to medical management may have a negligible impact on epileptogenesis. The exact mechanism(s) underlying poststroke seizure development due to hemorrhage remains unclear. High levels of iron in hemosiderin deposited after a hemorrhage may cause focal epilepsy 28 and may have an epileptogenic effect on cortical neurons. 25 Another possible mechanism is the dysfunction of the blood-brain barrier and the accumulation of albumin within astrocytes acting as an epileptogenic trigger. 29 This lends weight to the need for larger, controlled studies with 2 treatment groups to compare the rates of poststroke seizures after endovascular therapy versus medical management. It is important to note that of the 10 patients with both poststroke seizures and HT, 8 patients had petechial hemorrhage
depicts the inclusion and exclusion criteria for analysis in this study without a space-occupying effect. These patients would not have met the usual criteria of "symptomatic" HT, which is often defined as PH2 with symptomatic decline. 15 This suggests that radiologically defined hemorrhage, regardless of symptoms, may be clinically relevant for its association with seizure development.
We observed a trend of long median time to the first seizure in the group with HT, compared to the group without HT (Table 1) . This is consistent with previous reports that hemorrhage is associated with seizures occurring later, 11 and this observation may contribute to further discussion for the need to monitor patients in the late stage.
Although some studies have divided poststroke seizures into early and late seizures, with 7 days often used as the cut-off time, 30 hemorrhage has been shown to be implicated in both early 10, 25 and late seizures, 16, 23 implying a possible mechanistic link. 8 Our study has limitations. Despite having a relatively large, single-center cohort of acute stroke patients treated with endovascular therapy, the sample size of patients with poststroke seizures was limited. Identification of HT was based on imaging at 24-48 hours, consequently HT that occurred after 48 hours might have been missed. MRI was used in a minority (10.7%) of patients instead of CT, which may differ in the sensitivity for HT detection. However, any confounding effect should be minimal, given that only 2 of the patients who developed seizures were imaged with MRI, which detected HT in 1 patient. Commencement of AEDs in a minority of patients would have reduced their seizure risk, thereby underestimating the risk of seizure recurrence. Determining seizure diagnosis by phone interview may have been affected by recall bias and overestimation of seizure incidence. Conversely, underestimation may have occurred due to underrecognition of more subtle seizures. This was minimized by corroboration of patient recall with medical records. Furthermore, the possibility of endovascular therapy causing HT cannot be ruled out.
| CONCLUSIONS
Patients with anterior circulation strokes who developed HT after treatment with endovascular therapy were nearly 5 times more likely to experience poststroke seizures compared to those without HT. Furthermore, the HT that is clinically associated with the development of seizures is radiologically defined, regardless of symptoms. HT has the potential to be used as an imaging marker when evaluating compounds with antiepileptogenic effects in patients after ischemic stroke. Given the increasing use of modern endovascular stroke therapies, larger controlled studies specifically comparing the seizure incidence following endovascular therapy and medical management are warranted.
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